DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns. Issue 6 (June 2020)

• Record Type: Journal Article
• Authors: Zheng, Kang; Kros, Johan M.; Li, Jin; Zheng, Ping-Pin
• Is Part Of: Drug discovery today. Volume 25:Issue 6(2020)
• Page Start: 951
• Page End: 955
• Publication Date: 2020-06
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2020.03.005
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: DNA NanorobotTh-ITI is an emerging powerful therapeutic modality for solid cancer. DNA NanorobotTh-ITI specifically induces tumor infarction and massive necrosis. DNA NanorobotTh-ITI is comparable with other effective anticancer modalities but with less toxicity. DNA NanorobotTh-ITI is being transitioned from the preclinical setting to clinical translation. New potential clinical concerns of DNA NanorobotTh-ITI are being raised. Further studies are required for addressing these new potential concerns. Abstract : DNA-nanorobot-guided thrombin-inducing tumor infarction (DNA NanorobotTh-ITI) is emerging as a powerful therapeutic strategy for treatment of solid cancers. The technology represents a major advance in the application of DNA nanotechnology for anticancer therapy. More importantly, the technology is being translated from preclinical studies to the clinic owing to its promising anticancer effects with fewer toxicities demonstrated in preclinical settings. However, despite these beneficial effects of the technology, it is important to point out that some important potential clinical concerns remain to be addressed. Here, we raise these clinical concerns along with these beneficial effects of the technology. Hopefully, these newly raised potential clinical concerns could drive forward research in this field to expedite its clinical translation.